CYP1A2 and metabolic disease: In this case, the patient experienced tizanidine-induced bradycardia at a low dose of tizanidine (2 mg) without drug interactions, metabolic disorders, or structural cardiac disease, and there was no history of sudden smoking cessation that could cause a rapid decrease in CYP1A2 enzyme activity.